MCRB
Price
$1.14
Change
+$0.07 (+6.54%)
Updated
Dec 4, 6:59 PM EST
92 days until earnings call
ORMP
Price
$2.14
Change
+$0.01 (+0.47%)
Updated
Dec 4, 6:59 PM EST
85 days until earnings call
Ad is loading...

MCRB vs ORMP ᐉ Comparison: Which is Better to Invest?

Header iconMCRB vs ORMP Comparison
Open Charts MCRB vs ORMPBanner chart's image
Seres Therapeutics
Price$1.14
Change+$0.07 (+6.54%)
Volume$1.5M
CapitalizationN/A
Oramed Pharmaceuticals
Price$2.14
Change+$0.01 (+0.47%)
Volume$58.79K
CapitalizationN/A
View a ticker or compare two or three
MCRB vs ORMP Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
MCRB vs. ORMP commentary
Dec 05, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MCRB is a StrongBuy and ORMP is a Hold.

COMPARISON
Comparison
Dec 05, 2023
Stock price -- (MCRB: $1.12 vs. ORMP: $2.14)
Brand notoriety: MCRB and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MCRB: 60% vs. ORMP: 75%
Market capitalization -- MCRB: $149.94M vs. ORMP: $88.75M
MCRB [@Biotechnology] is valued at $149.94M. ORMP’s [@Biotechnology] market capitalization is $88.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MCRB’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 1 green FA rating(s).

  • MCRB’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 1 green, 4 red.
According to our system of comparison, ORMP is a better buy in the long-term than MCRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MCRB’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 6 bullish TA indicator(s).

  • MCRB’s TA Score: 4 bullish, 3 bearish.
  • ORMP’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ORMP is a better buy in the short-term than MCRB.

Price Growth

MCRB (@Biotechnology) experienced а -3.45% price change this week, while ORMP (@Biotechnology) price change was -2.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.40%. For the same industry, the average monthly price growth was +26.79%, and the average quarterly price growth was +25.75%.

Reported Earning Dates

MCRB is expected to report earnings on Mar 06, 2024.

ORMP is expected to report earnings on Feb 28, 2024.

Industries' Descriptions

@Biotechnology (+5.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MCRB with price predictions.
OPEN
A.I.dvisor published
a Summary for ORMP with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MCRB($150M) has a higher market cap than ORMP($88.7M). MCRB (-80.000) and ORMP (-82.211) have similar YTD gains . ORMP has higher annual earnings (EBITDA): -15.96M vs. MCRB (-124.01M). ORMP (175M) and MCRB (170M) have equal amount of cash in the bank . ORMP has less debt than MCRB: ORMP (76M) vs MCRB (212M). MCRB has higher revenues than ORMP: MCRB (127M) vs ORMP (2.02M).
MCRBORMPMCRB / ORMP
Capitalization150M88.7M169%
EBITDA-124.01M-15.96M777%
Gain YTD-80.000-82.21197%
P/E RatioN/AN/A-
Revenue127M2.02M6,284%
Total Cash170M175M97%
Total Debt212M76M279%
FUNDAMENTALS RATINGS
MCRB vs ORMP: Fundamental Ratings
MCRB
ORMP
OUTLOOK RATING
1..100
2014
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
9764
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (33) in the Pharmaceuticals Other industry is somewhat better than the same rating for MCRB (66) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than MCRB’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MCRB (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to MCRB’s over the last 12 months.

ORMP's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as MCRB (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to MCRB’s over the last 12 months.

ORMP's Price Growth Rating (64) in the Pharmaceuticals Other industry is somewhat better than the same rating for MCRB (97) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than MCRB’s over the last 12 months.

ORMP's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as MCRB (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to MCRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MCRBORMP
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 6 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 14 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCVTX17.350.20
+1.17%
Fidelity Advisor® Small Cap Value M
DISSX25.89N/A
N/A
BNY Mellon Small Cap Stock Index Inv
PJDAX16.22N/A
N/A
PGIM Jennison Rising Dividend A
BSUIX9.32N/A
N/A
BlackRock Sustainable Intntl Eq Ins
DTCAX15.59N/A
N/A
BNY Mellon Sust US Equity A

MCRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, MCRB has been loosely correlated with MDGL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if MCRB jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MCRB
1D Price
Change %
MCRB100%
+4.67%
MDGL - MCRB
48%
Loosely correlated
+4.16%
AGIO - MCRB
42%
Loosely correlated
+0.70%
ORMP - MCRB
42%
Loosely correlated
+0.47%
NRIX - MCRB
39%
Loosely correlated
+8.83%
AXON - MCRB
38%
Loosely correlated
+2.09%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with SRNEQ. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then SRNEQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+0.47%
SRNEQ - ORMP
51%
Loosely correlated
+5.97%
KRYS - ORMP
48%
Loosely correlated
-1.26%
VXRT - ORMP
48%
Loosely correlated
+0.29%
AGEN - ORMP
46%
Loosely correlated
+6.23%
MORF - ORMP
46%
Loosely correlated
+2.13%
More